Pinta Capital Partners

DeLorean Artificial Intelligence is a company focused on developing advanced artificial intelligence products for healthcare and sales. Its Medical AI product predicts disease onset, transitions, and next best actions to improve patient health outcomes. This system is the first of its kind to be biologically validated and has been implemented at scale, impacting approximately 50% of renal patients in the United States and processing data from 45 million patients. The Medical AI solution has demonstrated significant cost savings, averaging $100 per member per month. In addition, DeLorean AI offers a Sales AI product tailored for both B2B and B2C markets, which is currently utilized by Fortune 500 companies. The company's business model operates on an AI as a Service framework, enabling organizations to leverage its predictive capabilities for various applications.